Jagsonpal Pharmaceuticals details sustainability efforts, customs penalty in 2025 report

Jagsonpal Pharmaceuticals Limited's Business Responsibility and Sustainability Report for the financial year 2024-25, part of its Annual Report, was submitted to both the BSE and NSE on September 1, 2025. The company, which markets and distributes pharmaceutical formulations, reported a turnover of ₹2687.16 million and a net worth of ₹2399.50 million as of March 31, 2025. Pharmaceutical formulations accounted for 97% of its total turnover.

The report details the company's commitment to sustainability, with exports contributing 1.3% to total turnover. Employee well-being measures, including health, life, accident, and maternity benefits, covered 100% of permanent male and female employees. The cost incurred on these measures represented 0.23% of the company's total revenue. The company also reported a total waste generated of 43.070 metric tonnes in FY 2024-25, up from 25.978 metric tonnes in FY 2023-24, with all waste being disposed of via incineration.

A significant disclosure in the report was a penalty of ₹5,09,79,206 from the Office of the Principal Commissioner of Customs for alleged incorrect classification of imported goods, for which an appeal has been preferred. Jagsonpal Pharmaceuticals had no reported instances of disciplinary action for bribery/corruption or product recalls due to safety issues in the financial year.